<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">ISOSORBIDE DINITRATE</span><br/>(eye-soe-sor'bide)<br/><span class="topboxtradename">Coronex <img border="0" src="../images/maple.gif"/>, </span><span class="topboxtradename">Dilatrate-SR, </span><span class="topboxtradename">Iso-Bid, </span><span class="topboxtradename">Isordil, </span><span class="topboxtradename">Isotrate, </span><span class="topboxtradename">Novosorbide <img border="0" src="../images/maple.gif"/>, </span><span class="topboxtradename">Sorbitrate, </span><span class="topboxtradename">Sorbitrate SA<br/></span><b>Classifications:</b> <span class="classification">cardiovascular agent</span>; <span class="classification">nitrate vasodilator</span><br/><b>Prototype: </b>Nitroglycerin<br/><b>Pregnancy Category: </b>C<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>2.5 mg, 5 mg, 10 mg sublingual tablets; 5 mg, 10 mg chewable tablets; 5 mg, 10 mg, 20 mg, 30 mg, 40 mg tablets; 40 mg sustained release tablets, capsules</p>
<h1><a name="action">Actions</a></h1>
<p>Organic nitrate with pharmacologic actions similar to those of nitroglycerin. Relaxes vascular smooth muscle with resulting
         vasodilation. Dilation of peripheral blood vessels tends to cause peripheral pooling of blood, decreased venous return to
         heart, and decreased left ventricular end-diastolic pressure, with consequent reduction in myocardial oxygen consumption.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Has an antianginal effect by causing vasodilation of the coronary arteries.</p>
<h1><a name="uses">Uses</a></h1>
<p>Relief of acute anginal attacks and for management of long-term angina pectoris.</p>
<h1><a name="unlabeleduses">Unlabeled Uses</a></h1>
<p>Alone or in combination with a cardiac glycoside or with other vasodilators (e.g., hydralazine, prazosin, for refractory CHF;
         diffuse esophageal spasm without gastroesophageal reflux and heart failure).
      </p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Hypersensitivity to nitrates or nitrites; severe anemia; head trauma; increased intracranial pressure. Safe use during pregnancy
         (category C) or lactation is not established.
      </p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Glaucoma, hypotension, hyperthyroidism.</p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Angina Prophylaxis</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> Regular tablets 2.530 mg q.i.d. a.c. and h.s.; Sublingual tablet 2.510 mg q46h; Chewable tablet 530
               mg chewed q23h; Sustained release tablets 40 mg q612h<br/><br/><span class="indicationtitle">Acute Anginal Attack</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> Sublingual tablet 2.510 mg q23h prn; Chewable tablet 530 mg chewed prn for relief<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Oral</span><br/><ul>
<li>Do not confuse with isosorbide, an oral osmotic diuretic.</li>
<li>Give regular oral forms on an empty stomach (1 h a.c. or 2 h p.c.). If patient complains of vascular headache, however, it
            may be taken with meals.
         </li>
<li>Advise patient not to eat, drink, talk, or smoke while sublingual tablet is under tongue.</li>
<li>Instruct patient to place sublingual tablet under tongue at first sign of an anginal attack. If pain is not relieved, repeat
            dose at 510 min intervals to a maximum of 3 doses. If pain continues, notify physician or go to nearest hospital emergency
            room.
         </li>
<li>Chewable tablet must be thoroughly chewed before swallowing.</li>
<li>Do not crush sustained release form. It must be swallowed whole.</li>
<li>Have patient sit when taking rapid-acting forms of isosorbide dinitrate (sublingual and chewable tablets) because of the possibility
            of faintness.
         </li>
<li>Store in tightly closed container in a cool, dry place. Do not expose to extremes of temperature.</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">Body as a Whole:</span> Hypersensitivity reaction, paradoxical increase in anginal pain, methemoglobinemia (overdose). <span class="typehead">CNS:</span> Headache, dizziness, weakness, <span class="speceff-common">lightheadedness,</span> restlessness. <span class="typehead">CV:</span> Palpitation, postural hypotension, tachycardia. <span class="typehead">GI:</span> Nausea, vomiting. <span class="typehead">Skin:</span> <span class="speceff-common">Flushing,</span> pallor, perspiration, rash, exfoliative dermatitis. 
      <h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span> <b>Alcohol</b> may enhance hypotensive effects and lead to cardiovascular collapse; <span class="classification">antihypertensive agents</span>, <span class="classification">phenothiazines</span> add to hypotensive effects. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> Significant first pass metabolism with PO absorption, with 1090% reaching systemic circulation. <span class="typehead">Onset:</span> 25 min SL; within 1 h regular tabs; within 3 min chewable tabs; 30 min sustained release tabs. <span class="typehead">Duration:</span> 12 h SL; 46 h regular tabs; 0.52 h chewable tabs; 68 h sustained release tabs. <span class="typehead">Metabolism:</span> Metabolized in liver. <span class="typehead">Elimination:</span> 80100% excreted in urine within 24 h. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Monitor effectiveness of drug in relieving angina.</li>
<li> 							Note: Headaches tend to decrease in intensity and frequency with continued therapy but may require administration of analgesic and
            reduction in dosage. 						
         </li>
<li> 							Note: Chronic administration of large doses may produce tolerance and thus decrease effectiveness of nitrate preparations. 						</li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Make position changes slowly, particularly from recumbent to upright posture, and dangle feet and ankles before walking.</li>
<li>Lie down at the first indication of light-headedness or faintness.</li>
<li>Keep a record of anginal attacks and the number of sublingual tablets required to provide relief.</li>
<li>Do not drink alcohol because it may increase possibility of light-headedness and faintness.</li>
<li>Do not breast feed while taking this drug without consulting physician.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>